Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;14(6):485-493.
doi: 10.1016/j.clgc.2016.04.016. Epub 2016 May 5.

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

David Lorente  1 , Aurelius Omlin  2 , Zafeiris Zafeiriou  1 , Daniel Nava-Rodrigues  1 , Raquel Pérez-López  1 , Carmel Pezaro  3 , Niven Mehra  1 , Elizabeth Sheridan  1 , Ines Figueiredo  1 , Ruth Riisnaes  1 , Susana Miranda  1 , Mateus Crespo  1 , Penny Flohr  1 , Joaquín Mateo  1 , Amelia Altavilla  1 , Roberta Ferraldeschi  1 , Diletta Bianchini  1 , Gerhardt Attard  1 , Nina Tunariu  1 , Johann de Bono  4
Affiliations

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

David Lorente et al. Clin Genitourin Cancer. 2016 Dec.

Abstract

Background: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB.

Materials and methods: A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and laboratory data and prebiopsy computed tomography parameters (Hounsfield units [HUs]) were determined. A score for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested in the validation set.

Results: Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40 (69%) in the validation set. On univariable analysis, hemoglobin (P = .019), lactate dehydrogenase (P = .003), prostate-specific antigen (P = .005), and mean HUs (P = .004) were selected. A score based on the LDH level (≥ 225 IU/L) and mean HUs (≥ 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set (odds ratio, 5.1; 95% confidence interval, 1.9%-13.4%; P = .001). The area under the curve of the score was 0.79 in the test set and 0.77 in the validation set.

Conclusion: BMB of the iliac crest is a feasible technique for obtaining tumor tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective studies of independent cohorts are needed to establish the external validity of the score.

Keywords: Biopsy; Bone marrow; Computed tomography; Hounsfield units; Molecular biology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Computed Tomography Parameters in the Posterior Iliac Crest
Figure 2
Figure 2
Hematoxylin and Eosin Staining of a Positive Bone Marrow Biopsy
Figure 3
Figure 3
Receiver Operating Characteristic Curve Analysis of the Test and Validation Sets
See this image and copyright information in PMC

References

    1. Ferlay J., Soerjomataram I., Ervik M. International Agency for Research on Cancer; Lyon: 2013. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11.http://globocan.iarc.fr Available at: Accessed April 13, 2014.
    1. Baca S.C., Prandi D., Lawrence M.S. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666–677. - PMC - PubMed
    1. Kumar A., Coleman I., Morrissey C. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22:369–378. - PMC - PubMed
    1. Yap T.A., Sandhu S.K., Workman P., de Bono J.S. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;10:514–523. - PubMed
    1. de Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–549. - PubMed